Guardant Health

$54.18 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Guardant Health

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Stock Analysis

last close $54.18
1-mo return 12.6%
3-mo return 75.6%
avg daily vol. 1.07M
52-week high 133.82
52-week low 27.65
market cap. $5.4B
forward pe -
annual div. -
roe -99.6%
ltg forecast -
dividend yield -
annual rev. $408M
inst own. 92.9%
baraka

Subscribe now for daily local and international financial news

Subscribe